Clinical Trials › NCT04874597
Active, Not Recruiting
Investigation of the Effect of Ocrelizumab on Peripheral Lymphocyte Immunophenotypes with Suppressive Capacity in MS
Sponsored by Dr Recai Turkoglu
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 30
Target enrollment
Nov 2021
Start date
Apr 2025
Expected completion
Interventions / Treatments
Ocrelizumab
Conditions studied
Multiple Sclerosis
Trial locations
U.S. site locations haven't been posted yet for this trial. Check ClinicalTrials.gov for the latest contact and location info.
The app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.